anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, progressive in nature, and known to have a negative impact on mortality, morbidity, and quality of life. Patients requiring acute termination of AF to restore sinus rhythm are subjected to electrical cardioversion, which requires sedation and therefore hospitalization due to pain resulting from the electrical shocks. However, considering the progressive nature of AF and its detrimental effects, there is a clear need for acute out-of-hospital (i.e., ambulatory) cardioversion of AF. In the search for shock-free cardioversion methods to realize such ambulatory therapy, a method referred to as optogenetics has been put forward. Optogenetics enables optical control over the electrical activity of cardiomyocytes by targeted expression of light-activated ion channels or pumps and may therefore serve as a means for cardioversion. First proof-of-principle for such light-induced cardioversion came from in vitro studies, proving optogenetic AF termination to be very effective. Later, these results were confirmed in various rodent models of AF using different transgenes, illumination methods, and protocols, whereas computational studies in the human heart provided additional translational insight. Based on these results and fueled by recent advances in molecular biology, gene therapy, and optoelectronic engineering, a basis is now being formed to explore clinical translations of optoelectronic control of cardiac rhythm. In this review, we discuss the current literature regarding optogenetic cardioversion of AF to restore normal rhythm in a shock-free manner. Moreover, key translational steps will be discussed, both from a biological and technological point of view, to outline a path toward realizing acute shock-free ambulatory termination of AF.
INTRODUCTION: Estimating the serum vancomycin (VCM) concentrations of lean and patients with obesity is challenging. Additionally, VCM dosing for Japanese patients undergoing hemodialysis remains particularly unclear. This study aimed to determine the impact of the physical build on serum VCM concentrations of Japanese patients undergoing hemodialysis.
METHODS: This retrospective cohort study included hospitalized patients undergoing hemodialysis, who received treatment with VCM between May 1, 2019, and December 31, 2021, at Kansai Rosai Hospital, which is a 642-bed acute care hospital in Japan. Patients were divided into the following three groups based on their body mass index (BMI): lean group (≤18.5 kg/m2), normal group (18.5-25 kg/m2), and obese group (≥25 kg/m2). The VCM dose and predialysis serum VCM concentration (PVC) were compared.
RESULTS: This study included 191 patients. There were 50 patients in the lean group, 85 in the normal group, and 56 in the obese group. The median loading doses per body weight were 24.0, 22.1, and 21.2 mg/kg for the lean, normal, and obese groups, respectively. The VCM dose per body weight decreased significantly with increasing BMI. The median PVCs of the lean and normal groups were approximately 15 mg/L (not significantly different). However, the median PVC of the obese group was 18.3 mg/L, which was significantly higher (P < 0.001).
CONCLUSIONS: The VCM dose per body weight for Japanese patients undergoing hemodialysis should be adjusted based on the BMI.
A bandage and method for securing a tension member comprising a central body and a plurality of tabs disposed about the central body. A tension member may be disposed across or through a slit or aperture of the central body. A body adhesive on the lower surface of the central body may secure the bandage to the patient. The tension member may then be pulled across the upper surface of the central body and a first tab may be folded over and adhered to the tension member and central body. The tension member may then be pulled back across the first tab and a second tab may be folded over and adhered to the tension member and first tab. Likewise, the tension member may then be pulled back across the second tab and a third tab may be folded over and adhered to the tension member and second tab.
The methods and systems described by the present invention enable managing a medical order provided to a patient, comprising: a) Receive a medical order provided to a patient that defines a plurality of medical activities to be performed in a predefined order. b) Automatically create a list of a plurality of tasks for each medical activity, each task is assigned with a tracking status. c) Automatically associate each task with at least one of a plurality of care providers. d) Automatically notify the at least one care provider using a client terminal about the respective associated task. e) Aggregate a plurality of input messages each indicative of a status of one of the tasks. f) Automatically update the tracking status according to the input messages during the period of the medical order. g) Outputting a dataset of the medical order which is indicative of the tracking status for each task.
FIELD: biotechnology, medicine, immunology. SUBSTANCE: invention relates to recombinant antibodies IL4 used for treatment of patients with disorders associated with functions of IL4. Invention involves chimeric and human antibodies IL4 Mab that are derivatives of highly effective antibodies Mab and containing their pharmaceutical compositions and methods of diagnosis and treatment. Advantage of invention consists of the development of antagonist of IL4 with high affinity that is able to decrease the level of eosinophilic inflammation. EFFECT: enhanced effectiveness of antagonist, valuable immunological properties. 25 cl, 3 tbl, 10 dwg, 8 ex
The present invention relates to methods of treating, reducing the incidence of, and/or preventing ischemic events in a patient receiving Percutaneous Coronary Intervention (PCI) comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering to the patient an additional therapeutic agent comprising P2Y  12  And (3) an inhibitor. The present invention relates to pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing ischemic events in patients receiving PCI. The pharmaceutical composition comprises cangrelor. The present invention relates to a method of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient receiving PCI, the method comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. Ischemic events may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and death.
Ten-eleven translocation (TET) 2 is an enzyme that catalyzes DNA demethylation to regulate gene expression by oxidizing 5-methylcytosine to 5-hydroxymethylcytosine, functioning as an essential epigenetic regulator in various biological processes. However, the regulation and function of TET2 in adipocytes during obesity are poorly understood. In this study, we demonstrate that leptin, a key adipokine in mammalian energy homeostasis regulation, suppresses adipocyte TET2 levels via JAK2-STAT3 signaling. Adipocyte Tet2 deficiency protects against high-fat diet-induced weight gain by reducing leptin levels and further improving leptin sensitivity in obese male mice. By interacting with C/EBPα, adipocyte TET2 increases the hydroxymethylcytosine levels of the leptin gene promoter, thereby promoting leptin gene expression. A decrease in adipose TET2 is associated with obesity-related hyperleptinemia in humans. Inhibition of TET2 suppresses the production of leptin in mature human adipocytes. Our findings support the existence of a negative feedback loop between TET2 and leptin in adipocytes and reveal a compensatory mechanism for the body to counteract the metabolic dysfunction caused by obesity.
INTRODUCTION: Oxygen is frequently prescribed in neurocritical care units. Avoiding hypoxaemia is a key objective in patients with acute brain injury (ABI). However, several studies suggest that hyperoxaemia may also be related to higher mortality and poor neurological outcomes in these patients. The evidence in this direction is still controversial due to the limited number of prospective studies, the lack of a common definition for hyperoxaemia, the heterogeneity in experimental designs and the different causes of ABI. To explore the correlation between hyperoxaemia and poor neurological outcomes and mortality in hospitalised adult patients with ABI, we will conduct a systematic review and meta-analysis of observational studies and RCTs.
METHODS AND ANALYSIS: The systematic review methods have been defined according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and follow the PRISMA-Protocols structure. Studies published until June 2024 will be identified in the electronic databases MEDLINE, Embase, Scopus, Web of Science, The Cochrane Library, Cumulative Index to Nursing and Allied Health Literature and ClinicalTrials.gov. Retrieved records will be independently screened by four authors working in pairs, and the selected variables will be extracted from studies reporting data on the effect of 'hyperoxaemia' versus 'no hyperoxaemia on neurological outcomes and mortality in hospitalised patients with ABI. We will use covariate-adjusted ORs as outcome measures when reported since they account for potential cofounders and provide a more accurate estimate of the association between hyperoxaemia and outcomes; when not available, we will use univariate ORs. If the study presents the results as relative risks, it will be considered equivalent to the OR as long as the prevalence of the condition is close to 10%. Pooled estimates of both outcomes will be calculated applying random-effects meta-analysis. Interstudy heterogeneity will be assessed using the I2 statistic; risk of bias will be assessed through Risk Of Bias In Non-Randomised Studies of Interventions, Newcastle-Ottawa or RoB2 tools. Depending on data availability, we plan to conduct subgroup analyses by ABI type (traumatic brain injury, postcardiac arrest, subarachnoid haemorrhage, intracerebral haemorrhage and ischaemic stroke), arterial partial pressure of oxygen values, study quality, study time, neurological scores and other selected clinical variables of interest.
ETHICS AND DISSEMINATION: Specific ethics approval consent is not required as this is a review of previously published anonymised data. Results of the study will be shared with the scientific community via publication in a peer-reviewed journal and presentation at relevant conferences and workshops. It will also be shared key stakeholders, such as national or international health authorities, healthcare professionals and the general population, via scientific outreach journals and research institutes' newsletters.
Injuries to the cervical spine and to its contents, the spinal cord, cause serious neurological deficits, with loss of motor function and sensitivity of the four limbs, resulting in quadriplegia. The level of the lesion separating the area without deficits, above the lesion, from the sub-lesional area depends on the extent of the spine injury (dislocation, fracture or trauma without final displacement), may cause spinal cord injuries of varying severity, which can range from the benign to a complete section that results in complete and irreversible sensorimotor deficits. Lesions from C1 to C4 are often immediately fatal or cause diaphragmatic paralysis (innervated by the phrenic nerve whose roots originate at C4). C4-C5 paraplegia and below are therefore compatible with life as they spare respiratory autonomy, although they lead to severe permanent disabilities, creating a state of severe dependence in subjects who are often young.

The problems created by these patients are those of an extremely heavy individual, family, and societal burden in addition to the individual drama. While paraplegics, by maintaining their motor skills and sensitivity of both upper limbs and back muscles can often reintegrate and find remarkable mobility with wheelchairs, this is not the case of quadriplegics who must be provided with substitutes in order to achieve an acceptable quality of life. This project offers a highly innovative approach by means of a motorized exoskeleton that enables standing, walking and the use of the upper extremities. The validation of the first step of this concept will pave the way for developing increasingly sophisticated exoskeletal neuroprostheses, aimed at giving these patients compatible and ever greater autonomy.
Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume.
An inhalation composition for the treatment of bacteria related diseases is provided. The disclosed composition may include a mixture of three or more API(s) and a micronized poloxamer composition. Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. According to an embodiment, an inhalation composition including one or more APIs may be delivered to the respiratory tract by employing inhalation devices, such as inhalers and nebulizers. Antibiotic inhalation composition may provide improved solubility and bioavailability for three or more API(s), such as levofloxacin, betamethasone, and clindamycin. Furthermore, the synergistic effect of micronized poloxamer composition may provide improved solubility and bioavailability of any suitable API.
Major Depressive Disorder (MDD) and generalized Social Anxiety Disorder (gSAD) are pervasive major public health problems. These disorders are characterized by emotion dysregulation, an inability or inefficiency to regulate negative and positive affect as reflected in common and disorder-specific symptoms (e.g., attentional bias to negative stimuli, excessive/inappropriate negative thoughts, hyperarousal, anhedonia, emotional blunting). Such dysregulation is believed to result from an imbalance between top-down 'emotion regulating' (ER) frontal nodes central in inhibitory control of bottom-up subcortical 'emotion-generating' (EG) nodes in a Fronto-Limbic Affect Regulation and Emotional Salience (FLARES) network. Therefore, successful treatment would be expected to 'normalize' neurofunctional disturbances in the FLARES network, which can be measured with fMRI and more distal units of brain function -- event-related potentials (ERPs) from electroencephalography, startle potentiation from electromyography (EMG), neurocognitive performance, and use of regulation strategies in daily life via self-report. The overarching objective of the proposed study is to understand how, when, and where CBT works and for whom to tailor treatment to improve clinical outcome.

Without precisely identified "targets" and "predictors" of change, CBT response will continue to be unpredictably varied with few achieving meaningful clinical improvement placing them at risk for relapse and recurrence. Our proposal builds on published data from our lab and others and Preliminary Data which shows FLARES function, as assayed with fMRI, ERPs, EMG, and behaviors, is sensitive to change following CBT.

Importantly, both baseline fMRI and non-fMRI units of brain-behavioral measures predict CBT response better than baseline clinical measures. Such knowledge can lead to more precise interventions aimed at capitalizing on 'strengths' or improving 'deficits' that may each exist before CBT and/or explain why CBT does not work for some patients. The dual development of fMRI ('mechanistic') and non-fMRI ('pragmatic') predictors and indices of therapeutic change is aimed at advancing precision medicine while increasing the clinical utility of 'biomarkers' in the outpatient setting. With this objective, we propose to employ well-validated paradigms to test ER and EG in the context of negative stimuli, reward processes, and fear systems in MDD and gSAD to delineate common and disorder-specific mechanisms of change and predictors of CBT outcome. We will enroll 200 patients: 100 MDD (without comorbid gSAD), 100 gSAD (without comorbid MDD) and randomize them to 12 weeks of manualized CBT or 12 weeks of 'placebo' psychotherapy (supportive therapy) (1:1 ratio). Multiple units of FLARES function will be collected in all patients before (Week 0), during (midway/Week 6) and after treatment (Week 12) to ascertain CBT 'dose' effects, and in 40 healthy controls for comparison. Pre-CBT predictors based on binary (responder/non-responder status) and continuous (extent of change) outcomes will be examined midway (Week 6), immediately after treatment (Week 12), and at 6-month follow-up.
Participants will receive Active tACS for 30 minutes prior conventional physical therapy program. They will be asked to perform this combination therapy for 15 sessions, occurring three times a week for five weeks.
PROBLEM TO BE SOLVED: To obtain the subject new substance having excellent antimicrobial activity, antimycotic activity and antitumor activity, thus useful as an antimicrobial agent, antimycotic agent or antitumor agent. SOLUTION: This new substance is a IT-143 substance (salt thereof) of the formula (R is H or methyl). In this substance of the formula, when R is methyl, the substance has the following physicochemical characteristics: disposition: lightly yellow oily substance; molecular formula: C29 H43 NO4 ; molecular weight: 469; specific rotatory power [α]D<25> :-13.9 (in methanol, at a concentration of c=0.18); solubility: soluble to methanol, chloroform, acetone, ethyl acetate, dimethyl sulfoxide, insoluble to water. This substance of formula I is obtained by culturing bacteria belonging to the genus Streptomyces (pref. Streptomyces sp. IT-143 strain) and then recovering the resultant cultured product.
Each participant will receive 12 weeks of RUTF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-month period.
PURPOSE: Speech and language disorders can negatively affect preschool children's communicative participation skills. Focus on the Outcomes of Communication Under Six-34 (FOCUS-34) is a valid and reliable scale that evaluates communicative participation in preschool children with speech and language disorders. This study aimed to establish the Turkish version of FOCUS-34 (FOCUS-34-TR) and investigate its validity and reliability.
METHOD: A total of 175 children with language disorders, speech sound disorders, and fluency disorders (aged 20-72 months) and their parents were included in the study. Parents were asked to complete the demographic information form, the FOCUS-34-TR scale, and the Ages and Stages Questionnaires: Social-Emotional (ASQ-SE) Turkish version. The construct validity, convergent and divergent validity, internal consistency, and test-retest reliability of the scale were investigated.
RESULTS: The FOCUS-34-TR had high values for internal consistency (α = .97) and test-retest reliability (r = .95). The correlations between the FOCUS-34-TR total score and its subscales were between .77 and .90. A moderately significant negative correlation was found between the FOCUS-34-TR scale and the ASQ-SE.
CONCLUSION: The Turkish version of FOCUS-34 is a valid and reliable scale that can be used in clinics and for research purposes to evaluate the communicative participation skills of Turkish-speaking preschool children with speech and language disorders.
The invention provides a healthcare product used for enhancing hypoxia tolerance and a preparation method thereof. The healthcare product is prepared from a preset amount of rhodiola rosea, ginseng, pseudo-ginseng and salvia miltiorrhiza. According to the method, the rhodiola rosea, the ginseng, the pseudo-ginseng and the salvia miltiorrhiza are smashed and subjected to alcohol extraction and water extraction, and then essence components of the materials are obtained. The healthcare product is convenient and easy to take, has the double effects of improving hypoxia tolerance and resisting fatigue, and can relieve injury to the body from hypoxia in the body, improve the fatigue state of the body and improve living quality. The healthcare product can promote blood circulation, increase the oxygen content of blood, dispel lactic acid accumulation, improve metabolism and help a patient to restore stamina, remove fatigue and relieve hypoxia symptoms. Thus, the product can play an important role in healthcare of suitable people and has great scientific value.
Participants receive placebo (saline) at 0,2 and 6 months and are followed up until end of EPOCH 1 (Day 546). At the end of EPOCH 1, participants will have the option to enroll in the optional extension study (EPOCH 2-passive safety follow-up phase), and the participants that will agree to continue their enrollment will be followed up until Month 48 after end of EPOCH 1.
The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
The invention discloses an anti-HRH 1 monoclonal antibody and application thereof in treatment of glioblastoma, belonging to the field of biological medicine. Wherein the anti-HRH 1 monoclonal antibody can specifically bind to the antigen polypeptide shown in any one of SEQ ID No. 1-SEQ ID No.5 and/or the full length of the heavy chain variable region thereof comprises the amino acid sequence shown in SEQ ID No.7, and the full length of the light chain variable region comprises the amino acid sequence shown in SEQ ID No. 12. The invention identifies HRH1 as a target for treating glioblastoma for the first time, and provides a new choice for prevention, treatment and/or prognosis of glioblastoma. The anti-HRH 1 monoclonal antibody can obviously inhibit the growth of glioblastoma cells, can inhibit the growth of glioblastoma, and has very important clinical application value.
The bicuspid aortic valve (BAV) is the most common congenital heart defect among adults, often leading to severe valve dysfunction and aortic complications. Despite its clinical significance, uncertainties persist regarding the impact of sports participation on the natural course of BAV disease. The SPREAD (Sport PRactice and its Effects on Bicuspid Aortic valve Disease) study is a multicenter and multinational project designed to investigate this relationship. This paper outlines the study's design, and objectives. The study is divided into two phases; phase one involves a cross-sectional analysis comparing aortic dimensions and valve function among competitive athletes with BAV, athletes with tricuspid aortic valves (TAV), and sedentary individuals with BAV. The second phase is a prospective, longitudinal follow-up aiming to evaluate the impact of regular sports training on disease progression. The SPREAD study seeks to provide evidence-based insights into the effects of sports participation on BAV disease progression, guiding clinical decision-making regarding sports eligibility and risk stratification for individuals with BAV.
PROBLEM TO BE SOLVED: To obtain a hair care cosmetic capable of imparting luster, glow and gloss to hair and excellent in a hair-protecting effect against UV light. SOLUTION: This hair care cosmetic is compounded with inorganic compound particles having a refractive index of >=1.8. The inorganic compound particles are preferably titanium dioxide particles or inorganic oxide particles containing the titanium dioxide, and includes the particles of TiO2 -SiO2 , TiO2 -Al2 O3 , TiO2 -ZrO2 , TiO2 -SiO2 -ZrO2 , and TiO2 -SiO2 -Al2 O3 . The average particle diameter of the inorganic oxide particles is 1-100nm, especially 2-80nm. When the average particle diameter is >100nm, the particles are often unevenly adhered to hair, and can not impart naturally beautiful luster to the hair. When the average particle diameter is <1nm, the stability of the particles themselves is lowered, and the dispersibility of the particles into the cosmetic is deteriorated.